1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Specialties
Stryker Corporation

Stryker Corporation

SYK.TO
Stryker CorporationCA flagToronto Stock Exchange
18.57
CAD
-0.37
- -
7.12BMarket Cap
Stryker Corporation
SYK.TO
(Toronto Stock Exchange)

Recent

price

18.57

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
18.47
21.49
22.75
23.83
25.56
26.41
30.27
33.27
36.36
39.8
38.22
45.38
48.78
54
59.3
65.71
67.49
Revenue per Share
3.21
3.48
3.41
2.66
1.36
3.82
4.4
2.73
9.5
5.57
4.26
5.29
6.23
8.34
7.86
8.49
9.74
Basic EPS, GAAP
3.44
3.13
3.8
4.47
4.09
1.89
3.81
2.57
5.45
4.12
7.43
7.26
5.38
8.26
9.15
11.21
12.28
Free Cash Flow per Basic Share
0.6
0.72
0.85
1.06
1.22
1.38
1.52
1.7
1.88
2.08
2.3
2.52
2.78
3
3.2
3.36
3.44
Dividend per Share
18.34
20.17
22.62
23.93
22.74
22.82
25.47
26.62
31.33
34.2
34.79
39.41
43.88
48.92
54.1
58.61
62.54
Book Value per Share
13.8
10.94
13.24
8.5
6.33
6.92
-0.84
-1.81
-2.66
-1.31
-13.95
-7.63
-8.32
-3.27
1.01
-6.67
-3.49
Tangible Book Value per Share
396
386
381
379
378
377
374
374
374
374
376
377
378
380
381
382
383
Basic Weighted Avg Shares
7,320
8,307
8,657
9,021
9,675
9,946
11,325
12,444
13,601
14,884
14,351
17,108
18,449
20,498
22,595
25,116
25,837
Sales/Revenue/Turnover
25.61
21.21
22.12
20.82
20.74
21.69
20.6
19.85
18.82
19.52
15.61
15.71
16.86
19.14
20.65
20.14
21.73
Operating Margin (%)
223
282
277
307
378
397
546
642
723
778
812
990
998
1,028
1,050
1,193
1,221
Depreciation Expense
1,273
1,345
1,298
1,006
515
1,439
1,647
1,020
3,553
2,083
1,599
1,994
2,358
3,165
2,993
3,246
3,729
Net Income, GAAP
26.37
20.23
23.87
17
55.6
17.06
14.26
50.56
- -
18.7
18.17
12.58
12.11
13.83
14.29
28.09
27.56
Effective Tax Rate (%)
17.39
16.19
14.99
11.15
5.32
14.47
14.54
8.2
26.12
13.99
11.14
11.66
12.78
15.44
13.25
12.92
14.43
Profit Margin (%)
6,027
5,367
6,272
5,678
4,223
4,441
4,713
4,508
4,926
6,658
4,666
5,468
3,972
4,597
7,231
6,961
7,734
Working Capital
996
1,751
1,746
2,739
3,246
3,230
6,686
6,590
8,486
10,231
13,230
12,472
11,857
10,901
12,188
14,859
14,192
LT Debt
7,174
7,683
8,597
9,047
8,595
8,511
9,550
9,980
11,730
12,807
13,084
14,877
16,616
18,593
20,634
22,420
23,988
Total Equity
18.49
15.85
14.64
14.02
7.21
14.07
13.78
7.24
- -
10.34
7.17
8.61
9.56
10.98
12.05
9.96
10.62
Return on Invested Capital (%)
17.19
15.55
13.1
9.08
4.22
11.48
11.37
6.06
- -
9.16
6.27
7.33
8.27
11.36
10.16
10.16
10.27
Return on Capital (%)
18.49
18.11
15.95
11.4
5.84
16.82
18.24
10.45
32.75
16.98
12.35
14.26
14.97
17.98
15.26
15.08
16.51
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,000
499
750
LT Borrowings
14,859
14,224
14,192
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
382
383
384
Market Capitalization
- -
- -
5,802

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
14,755
13,338
14,418
Cash, Cash Equivalents & STI
4,100
2,965
3,476
Accounts Receivable, Net
4,039
3,571
3,743
Inventories
5,310
5,419
5,521
Total Current Liabilities
7,794
6,315
6,684
Payables & Accruals
5,199
4,931
4,829
ST Debt
1,000
499
750
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.25%
11.39%
8.66%
Free Cash Flow
29.71%
12.11%
22.83%
Net Income, GAAP
24.03%
16.04%
8.45%
Sales/Revenue/Turnover
9.84%
11.91%
11.16%
Total Cash Common Dividend
9.46%
8.29%
5.33%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,243
5,422
5,494
6,436
22,595
2025
5,866
6,022
6,057
7,171
25,116
2026
6,020
6,589
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.07
2.17
2.19
1.43
7.86
2025
1.71
2.31
2.25
2.22
8.49
2026
1.95
3.33
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.8
0.8
0.8
0.8
3.2
2025
0.84
0.84
0.84
0.84
3.36
2026
0.88
0.88
- -
- -
- -
Similar Companies
Seegene, Inc. (096530.KQ)
Lumos Diagnostics Holdings Limited (LDX.AX)
AI Maverick Intel, Inc. (AIMV)
Alcon AG (0A0D.IL)
Genex Pharmaceutical, Inc. (GENX)
IVF Hartmann Holding AG (VBSN.SW)
Business
Stryker Corporation is a medical technology company that develops, manufactures and markets orthopaedic implants; surgical and neurotechnology products; medical and surgical equipment; patient handling, emergency medical and intensive care products; endoscopic and communications systems; and digital and robotic-enabled solutions for hospitals, ambulatory surgery centers and other healthcare providers. Founded in 1941 and headquartered in Portage, Michigan, the company operates globally through company-owned subsidiaries, branches and distributors, serving customers in approximately 75 countries. Its business is organized primarily into MedSurg and Neurotechnology and Orthopaedics, with product lines spanning Instruments, Endoscopy, Medical, Vascular, Neuro Cranial, Knees, Hips, Trauma and Extremities, and related technologies, including Mako robotic-arm assisted surgery systems and other surgical planning and navigation platforms. In 2025, Stryker expanded through the acquisition of Inari Medical, strengthening its peripheral vascular portfolio, while also completing other acquisitions during the year and reporting the sale of its U.S. spinal implants business as part of a portfolio reshaping. In 2026, the company continued its expansion strategy by completing the acquisition of Amplitude Vascular Systems to add intravascular lithotripsy technology, announcing a definitive agreement to acquire ZuriMED to enhance its shoulder offering, and launching new products including the Gamma4 Hip Fracture Nailing System in Europe, reflecting ongoing investment in new technologies and targeted portfolio growth.